Takeda has discovered first-of-its-kind EOHILIA (budesonide oral suspension), the only FDA-approved oral therapy tailored for individuals aged 11 and above grappling with eosinophilic oesophagitis.These innovative single-dose stick packs, each containing 2 mg/10 mL, are set to hit the market by the end of February.
EOHILIA, a corticosteroid designed for a 12-week treatment regimen in individuals aged 11 years and older with EoE, features a unique budesonide formulation engineered specifically for this condition. Notably, EOHILIA's innovative composition grants it thixotropic properties, allowing it to flow more freely when agitated and revert to a thicker consistency when swallowed.
With EOHILIA, patients and their physicians now have access to the inaugural FDA-approved oral treatment option for eosinophilic oesophagitis, which in two 12-week clinical studies, demonstrated efficacy in reducing esophageal inflammation and enhancing swallowing function.
EoE is a chronic inflammatory condition localised in the oesophagus, characterised by immune-mediated responses. While the exact cause remains elusive, it is believed to be triggered by various factors, including specific foods and environmental allergens. Symptoms of EoE, such as difficulty swallowing, vomiting, and discomfort, vary among individuals and age groups.
Identifying eosinophilic oesophagitis can be challenging, often resulting in delayed identification among patients. Left untreated, EoE-induced inflammation can exacerbate, leading to esophageal narrowing and the risk of food impaction, a common cause of emergency room visits.
With the FDA's approval of EOHILIA, patients and healthcare providers now have access to the first FDA-approved oral treatment option for EoE in the United States, offering promising relief for individuals grappling with this complex condition.
